[1] HAN B, ZHENG R, ZENG H, et al.Cancer incidence and mortality in China, 2022.[J]. J Nat Cancer Center, 2024, 4(1): 47-53.
[2] 中华人民共和国国家卫生健康委员会医政司.原发性肝癌诊疗指南(2024年版)[J/CD].肝癌电子杂志,2024,11(2):1-26.
[3] WEI W, JIAN P E, LI S H, et al.Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety[J]. Cancer Commun (Lond), 2018,38(1):61.
[4] WANG Z, REN Z, CHEN Y, et al.Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study[J]. Clin Cancer Res, 2018, 24(9):2074-2081.
[5] CHEN B, WU J X, CHENG S H, et al.Phase 2 study of adjuvant radiotherapy following narrow-margin hepatectomy in patients with HCC[J]. Hepatology, 2021, 74(5): 2595-2604.
[6] QIN S, CHEN M, CHENG A L, et al.Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 tria[J]. Lancet, 2023, 402(10415): 1835-1847.
[7] YOPP A, KUDO M, CHEN M, et al.Updated efficacy and safety data from IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab vs active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma // ESMO, Barcelona, Spain, 2024.
[8] WANG Z, FAN J, ZHOU S L, et al.BA39 Updated efficacy and safety data from IMbrave050: phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)[J]. Ann Oncol, 2024, 35(Suppl 2): S1230.
[9] SANGRO B, KUDO M, ERINJERI J P, et al.Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 stud[J]. Lancet, 2025, 405(10474):216-232. |
